The cardinal motor symptoms of Parkinson's disease (PD) are caused by the vulnerability to dysfunction and degeneration of ventral midbrain (VM) dopaminergic (DA) neurons. A major limitation for experimental studies of current ES/iPS cell differentiation protocols is the lack of VM DA neurons with a stable phenotype as defined by an expression marker code of FOXA2/TH/β-tubulin. Here we demonstrate a combination of three modifications that were required to produce VM DA neurons. Firstly, early and specific exposure to 10 −8 M (low dose) retinoic acid improved the regional identity of neural progenitor cells derived from human ES cells, PD or healthy subjectspecific iPS cells. Secondly, a high activity form of human sonic hedgehog established a sizeable FOXA2 + neural progenitor cell population in vitro. Thirdly, early exposure to FGF8a, rather than Fgf8b, and WNT1 was required for robust differentiation of the FOXA2 + floor plate-like human neural progenitor cells into FOXA2 + DA neurons.
Introduction
The adult central nervous system (CNS) contains numerous neuronal types with distinct functional characteristics that regulate up to 100 trillion synapses in the most complex vertebrate brains (Pfaff, 2008) . Of relevance to Parkinson's disease (PD) research, the adult brain contains at least 10 types of dopaminergic (DA) neurons (for review see (Ang, 2006) ). Different types of DA neurons exhibit region-specific innervation patterns and cell type-specific transcriptional, electrophysiological and neurochemical profiles (Chung et al., 2005; McRitchie et al., 1996; Neuhoff et al., 2002; Wolfart et al., 2001) . The cardinal motor symptoms of PD are caused by the relative vulnerability of a specific type of DA neuron in the patient's ventral midbrain (VM) to degeneration. The substantia nigra A9 type (SN-A9) DA neurons are relatively more vulnerable to significant degeneration than neighboring ventral tegmental area A10 type (VTA-A10) DA neurons (Damier et al., 1999; German et al., 1989; German et al., 1992; Hirsch et al., 1988) . With respect to cell therapy for PD, both SN-A9 and VTA-A10 DA neurons exhibit widespread and dense patterns of axonal arborization (Matsuda et al., 2009 ) but transplanted fetal SN-A9 DA neurons are responsible for appropriate striatal reinnervation and improved drug-induced and spontaneous behavioral measures in models of PD (Grealish et al., 2010; Isacson et al., 2003) .
Human embryonic stem (ES) cells are a well-described source of DA neurons (Perrier et al., 2004) . With recent progress in cellular reprogramming technology, PD patient specific DA neurons can be generated from induced pluripotent stem (iPS) cells that retain authentic PD risk loads and so can be used for mechanistic studies of PD pathogenesis and drug screening (Soldner et al., 2009 ). Importantly, iPS cell technology could provide isogeneic cells for cell therapy to eliminate the patient's immune response to the transplanted neurons. The brain is relatively immunoprivileged but activated microglia can compromise the synaptic function of transplanted neurons (Soderstrom et al., 2008) . Nonetheless, the ability of human ES/iPS cells to differentiate in vitro into VM DA neurons that possess the intrinsic properties required for PD modeling or reinnervation after transplantation remains unclear.
Neuronal differentiation of mouse and human ES cells favors telencephalic cell fates (Gaspard et al., 2008; Li et al., 2009 ), but several strategies for directed differentiation towards mesencephalic cell fates have been described (Cho et al., 2008; Perrier et al., 2004; Molecular and Cellular Neuroscience 45 (2010) [258] [259] [260] [261] [262] [263] [264] [265] [266] Roy et al., 2006) . However, the ES/iPS cell differentiation protocols do not generate a robust VM DA neuron phenotype as shown by modest behavioral outcomes after transplantation (Chiba et al., 2008; Roy et al., 2006; Sonntag et al., 2007; Yang et al., 2008) . The issue of phenotypic robustness of human stem cell-derived DA neurons is compounded by the paucity of DA neuron subtype-specific immunocytochemical markers. For example, SN-A9 but not VTA-A10 DA neurons express the G protein coupled inward rectifying current potassium channel type 2 (GIRK2) in the human ventral midbrain (Mendez et al., 2005) . Tyrosine hydroxylase (TH) and GIRK2 coexpression has been adopted as a phenotypic marker of stem cellderived SN-A9 DA neurons (Roy et al., 2006 ). Yet forebrain DA neuron subtypes can also coexpress Girk2 and TH (O. Cooper, unpublished observation). Therefore, coexpression of these markers is particularly powerful only when discerning SN-A9 DA neurons from VTA-A10 DA neurons within the ventral midbrain. Recent developmental studies have demonstrated the role of the forkhead transcription factor, FoxA2/HNF3β in specifying and maintaining the VM DA neuron phenotype (Ferri et al., 2007; Kittappa et al., 2007; Lin et al., 2009) . Remarkably, immunocytochemical detection of FOXA2 expression by ES/iPS cell-derived DA neurons has not been described, and is conspicuous by its absence from existing mouse and human pluripotent stem cell differentiation protocols (Cai et al., 2009) .
In the present study, we found that FOXA2 expressing VM DA neurons were not generated by a recently described differentiation protocol . We hypothesized that the regional specification of the differentiation protocol was inadequate. To address this deficiency, we demonstrated that early and specific exposure to retinoic acid (RA) improved the regional identity of neural progenitor cells derived from human ES cells but the differentiated DA neurons did not express the key transcriptional regulator of the VM DA phenotype, FOXA2. To further improve sonic hedgehog (SHH) function in the differentiation protocol, we used a high activity form of human SHH to establish a sizeable FOXA2 + neural progenitor cell population in vitro from human ES or iPS cells. Since Fgf8 splice variants and Wnt1 are also important for the development of the embryonic midbrain (Muhr et al., 1999; Nordstrom et al., 2002 Nordstrom et al., , 2006 Olsen et al., 2006) , we tested the functions of recombinant FGF8a, Fgf8b and WNT1. We found that early exposure to FGF8a, rather than Fgf8b, and WNT1 were required for robust differentiation of the FOXA2 + floor plate-like neural progenitor cells into FOXA2 + DA neurons. In combination, these factors generated FOXA2 + DA neurons.
Results

Specific midbrain regionalization in response to retinoic acid
To understand the range of human DA neuron subtypes generated by our previously published protocol and others (Cai et al., 2009; Perrier et al., 2004) In response to these data, we designed experiments to improve the regional specification of the ES cell-derived human DA neurons in culture. We examined a range of retinoic acid (RA) concentrations towards inducing a midbrain-like transcriptional profile. Using human neural progenitor cells, RA concentration-dependent transcriptional profiles were determined after 22 days of differentiation in the absence or presence of 10 −6 , 10
, 10 −8 or 10 −9 M RA (Fig. 1A ).
Higher concentrations of RA (10 −6 M and 10 −7 M) reduced OTX2 and PAX2 levels and increased HOXB1 levels relative to differentiation conditions without RA (Fig. 1B) To improve the efficiency of ventralization in our RA-treated human neural progenitor cell cultures, we focused our attention to the recombinant Shh protein used in our previous differentiation protocol . As a first step to increasing the yield of FOXA2 expressing neural progenitor cells, we increased the concentration of the recombinant N-terminus truncated form of mouse Shh from 200 ng/ml to 500 ng/ml. At 500 ng/ml, few FOXA2 expressing progenitor cells were observed (data not shown). Next, we exposed the neural progenitor cells to Shh for an additional 7 days without increasing the yield of FOXA2 expressing neural progenitor cells (data not shown).
As an alternative to the recombinant N-terminal truncated form of mouse Shh, we decided to examine a recombinant human SHH protein with an N-terminal mutation that significantly increases protein signaling (SHH-C24II) (Taylor et al., 2001) . Importantly, the concentration of SHH-C24II markedly changed the yield of FOXA2 expressing progenitor cells that differentiated from RA-treated human ES and PD iPS cells. Furthermore, we explored the ability of another possibly critical reagent in VM DA neurogenesis, FGF8 splice variants (Olsen et al., 2006) . At DIV19 ( Fig. 2A -1).
FOXA2 + neural progenitor cell neurogenesis requires exposure to FGF8a rather than Fgf8b during neural induction and expansion
To examine the neurogenic potential of the human neural progenitor cell populations generated by these experimental conditions, we replaced Fgf8 and Shh in the culture medium with cAMP, TGFβ3 and GDNF as described . DA neurogenesis from FOXA2 expressing neural progenitor cells required prior exposure to FGF8a but not Fgf8b (Fig. 4) . After 49 days of differentiation (Fig. 4A) (Fig. 6F ).
To examine whether MS5-feeder cells were required for the differentiation of human FOXA2 + DA neurons, human pluripotent stem cell lines were differentiated on gelatin-coated dishes using the previously described recombinant protein supplement (Fig. 7A ). At DIV16, brightfield microscopy revealed human cultures composed of large cellular masses that exhibited long radial outgrowth consistent with neural differentiation (Figs. 7B,C) . Upon neuronal differentiation, the dissociated cultures exhibited many cells that coexpressed TH, β-tubulin and FOXA2 (Figs. 7D,E) .
Discussion
In these experiments, we found that a combination of a specific concentration of RA, high levels of a high activity form of human SHH and exposure to FGF8a and WNT1 was sufficient to direct the fate of human ES/iPS cells towards VM DA neurons.
Early studies of human ES cell directed differentiation generated functional DA neurons (Perrier et al., 2004) . While the ability to produce dopamine is an important attribute of neurons required for cell therapy and in vitro assays of PD neurodegeneration, the SN-A9 DA neuron subtype is the optimal dopaminergic neuron subtype for several reasons (Isacson et al., 2003) . SN-A9 DA neurons regulate motor function and their degeneration contributes to the cardinal symptoms of PD (Damier et al., 1999; German et al., 1989; German et al., 1992; Hirsch et al., 1988) . After transplantation into a PD model, fetal SN-A9 DA neurons reinnervate and increase c-Fos levels in the dorsolateral striatum, leading to improved amphetamine-induced rotations and spontaneous paw reaching activity (Grealish et al., 2010) . While these cellular attributes are clearly desirable, few phenotypic markers are available that clearly identify human VM DA neurons. Recent studies have established the transcription factor FoxA2 as a robust cellular marker of VM DA neurons through several stages of development (Ferri et al., 2007; Lin et al., 2009) . By using immunocytochemistry to identify FOXA2 expressing cells, we were rarely able to identify VM DA neurons differentiated from human ES cells using an established coculture-based differentiation protocol (Perrier et al., 2004; Sonntag et al., 2007) . This finding was surprising but complements a report of an alternative but similarly widely used embryoid body-based human ES/iPS cell differentiation protocol (Cai et al., 2009) . Instead, the presence of many ISL1 + DA neurons that likely represented a subthalamic A13 DA neuron cell fate (Mastick and Andrews, 2001) suggested that the specification of the human ES cellderived neural progenitors required both stronger posteriorizing and ventralizing cues to direct differentiation further from default telencephalic cell fates and generate a meaningful yield of SN-A9 DA neurons (Ang, 2006; Li et al., 2009; Marin et al., 2005; Mastick and Andrews, 2001) . RA is one-such example of a potent inducer of specific neural cell fates in a dose-dependent manner in several species including human (Maden, 2007) . However, differentiation protocols using RA (10
-10 −7 M) were intended to accomplish extensive shifts in cell fate away from the dorsal telencephalon towards motor neuron differentiation (Hu and Zhang, 2009 ). Using human ES cells, we found that 10 −8 M RA generated a midbrain-like transcriptional profile consistent with similar studies using mouse ES cells (Okada et al., 2004) but contrasts with a recent study of human ES cell differentiation that did not detect increased levels of EN1 with 10 −8 M RA (Li et al., 2009 ). The latter study used an embryoid bodybased differentiation protocol, which may explain the low level of EN1 expression observed at a similar RA concentration. Upon differentiation of RA-treated neural progenitor cells, we observed significantly fewer ISL1 expressing DA neurons without FOXA2 expression. Given that diencephalic DA neuron subtypes are poorly characterized, the increased yield of ISL1 − /FOXA2 − DA neurons suggested a phenotypic shift from subthalamic A13 DA neurons towards a more posterior but still dorsal hypothalamic ISL1 − A11 DA spinal projection neuron phenotype (Earley et al., 2009; Qu et al., 2006) . While the RA-induced phenotype suggested midbrain regionalization, the lack of FOXA2 expression still suggested inappropriate cell fate specification in the dorsoventral axis.
While Shh is biochemically connected with FoxA2 (Chiang et al., 1996; Roelink et al., 1995; Sasaki et al., 1997) , increasing the concentration of recombinant mouse Shh protein did not induce FOXA2 expression by neural progenitor cells. Our alternative strategy was based upon biochemical studies of SHH function that used Nterminal modifications to improve the induction of alkaline phosphatase activity in C3H10T1/2 cells by 8-fold (Taylor et al., 2001) . Consistent with these biochemical findings, the recombinant Nterminal high activity human SHH protein induced a dose-dependent increase in the FOXA2 + cellular phenotype. The high dose of an activated form of recombinant protein required to efficiently change cellular fates highlights the functional problems of generating biologically-relevant recombinant proteins and the cost of using them for experimental or cell therapeutic applications. By DIV49, the different functions of the FGF8 splice variants became apparent. During the early stages of ES/iPS cell differentiation (up to DIV19), both FGF8 proteins supported the generation of FOXA2 expressing progenitor cells. However by DIV49, increased yields of FOXA2 expressing cells required exposure to recombinant FGF8a protein rather than Fgf8b. Due to the heterogeneity and asynchronicity of cell fates during differentiation, human ES cells are not amenable to mechanistic studies of late cell fate specification and our studies do not directly discern the molecular mechanisms for neurogenesis from FOXA2 + progenitor cells. Yet, the different numbers of FOXA2 expressing cells induced by either FGF8a or Fgf8b splice variants at DIV19 and DIV49 may represent an in vitro selection pressure to eliminate non-neural FOXA2 + cell types with a concomitant promotion of ventral midbrain neuronal differentiation.
In line with such an interpretation, robust neuronal differentiation of FOXA2 expressing neural progenitor cells was observed only after exposure to FGF8a. In these cultures, the presence of calbindin expressing VM DA neurons demonstrates a commitment to the A10 DA neuron phenotype (Mendez et al., 2005 ). Yet, the low levels of GIRK2 throughout the cultures at this time point do not represent a lack of an A9 DA neuron phenotype (Mendez et al., 2005) . Instead, the cultures are likely to be too immature to express this type of functional potassium channel, especially since A9 DA neurons are considered to develop at a slow rate than A10 DA neurons (Joksimovic et al., 2009a) . In the embryonic brain, FoxA2 expressing neural progenitor cells generate several neuronal populations, not just VM DA neurons (Joksimovic et al., (Lee et al., 1997; Liu et al., 1999; Olsen et al., 2006) . Our studies of the requirement for exogenous WNT1 signaling during human ES cell differentiation into VM DA neurons are interesting for two reasons. Firstly, early exposure of human ES/iPS cells to recombinant WNT1 was required to generate appropriately patterned VM neural progenitor cells, consistent with developmental studies in the embryo (Muhr et al., 1999; Nordstrom et al., 2002; Nordstrom et al., 2006) . Secondly, in the context of recent studies of temporal changes in WNT expression during VM DA neurogenesis (Joksimovic et al., 2009b) , our findings of neuronal differentiation of FOXA2 + neural progenitor cells without exogenous SHH antagonism are important. This suggests that either SHH antagonists secreted in vitro are sufficient to induce neuronal differentiation or that SHH antagonism is a modest requirement for VM DA neurogenesis in human cells. Finally, our progress in generating human VM DA neurons without mouse feeder cells provides an opportunity for standardized differentiation conditions free of xenogeneic products that are likely to be required when providing ES/iPS cell-derived neurons for transplantation into PD patients (Mallon et al., 2006) . In summary, we have used new phenotypic markers to show that a previously described human ES cell differentiation protocol does not generate VM DA neurons . Several groups have observed the lack of human VM DA neuron differentiation from human ES cells without a significant improvement being proposed (Cai et al., 2009; Erceg et al., 2009) . We have now successfully generated human VM DA neurons by targeting both early posteriorizing and ventralizing neural patterning pathways. The markedly improved yield of VM DA neurons from human ES and iPS cells highlights an opportunity to enhance or modify exogenous signaling cues required to specify these cell types. Although isolated non-neural cell types may remain in these cultures, recent progress in flow cytometry can enrich the neuronal component to provide a robust cell source for new bioassays, drug discovery and cell based therapies for PD (Pruszak et al., 2009; Pruszak et al., 2007) . -21Puro-26 (XY) and PDB 1lox 21Puro-28 (XY) were generated from parental fibroblast cell lines derived from healthy subjects or patients with sporadic Parkinson's disease and obtained from Coriell Cell Repositories as described (Soldner et al., 2009) . Human ES/iPS cells were propagated as described . The differentiation of human ES/ iPS cells was adapted from a published protocol using MS5 feeder cells . Neuroectodermal differentiation was achieved using serum replacement medium (SRM) for 11 days, followed by N2 medium (DMEM/F-12; Invitrogen Corporation, Carlsbad, CA) (N2-A; Stem Cell Technologies, Vancouver, BC, Canada) for 3 days supplemented with 600 ng/ml Noggin (R&D Systems, Inc., Minneapolis, MN), 100 ng/ml human WNT1 (PeproTech EC Ltd., London, UK), 100 ng/ml human FGF8a or mouse Fgf8b (R&D Systems) and all-trans retinoic acid (Sigma-Aldrich, St. Louis, MO) to the culture medium.
Experimental methods
Human pluripotent stem cell culture and in vitro differentiation
The amino acid sequences of mouse Fgf8a and human FGF8a are identical but the cDNA sequences are distinct. Media were changed every 2 days. At day 14 of differentiation, total human neuroectodermal colonies were manually picked as described (Karki et al., 2006) and replated on polyornithine and laminin-coated culture dishes in N2 medium supplemented with growth factors. Neural progenitor cells were differentiated toward the DA neuron phenotype with mouse sonic hedgehog (Shh-N), high activity human sonic hedgehog (SHH-C24II), mouse fibroblast growth factor 8b (FGF8b), human FGF8a (all from R&D Systems, Inc.), 20 ng/ml brain derived neurotrophic factor (BDNF) (PeproTech EC Ltd), 1 ng/ml transforming growth factor type β3 (TGF-β3) (Calbiochem, San Diego, CA), 10 ng/ml glial cell line-derived neurotrophic factor (GDNF), 0.5 mM dibutyryl cAMP, and 0.2 mM ascorbic acid (AA) (all from SigmaAldrich). After 21 days (Day 35) cells were passaged using Tryple (Invitrogen Corporation) and spun at 1000 rpm for 5 min. Cells were resuspended in N2 medium and plated again at a density of approximately 1,000,000-2,000,000 cells per well (24 well plate) on polyornithine/laminin-coated dishes in the presence of BDNF, AA, SHH, and FGF8. After an additional 7 days of culture (DIV42), cells were differentiated until Day 49 without SHH and FGF8 but in the presence of BDNF, AA, cAMP, GDNF, and TGF-β3. For feeder-free conditions, 3 colonies of each human pluripotent stem cell line were propagated in human ES cell medium on a 6 well gelatin-coated dish and passaged twice using Accumax (Millipore, Billerica MA) to remove contaminating fibroblasts. For differentiation, human pluripotent stem cells were exposed to recombinant proteins as described. At DIV35, neural cells were split using Tryple (Invitrogen Corporation) and replated for continued growth until DIV49.
Quantitative real-time polymerase chain reaction RNA was purified and real-time polymerase chain reaction (PCR) was performed as described (Chung et al., 2005) . For primer sequences, see Supplementary Methods Table 1 . Relative gene expression differences were quantified using the 2 −ΔΔCT method (Livak and Schmittgen, 2001 ).
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde and analyzed by indirect immunofluorescence . Fluorescent signals were examined using an LSM510 Meta confocal microscope equipped with ultraviolet, argon, and helium-neon lasers (Carl Zeiss, Thornwood, NY). The following primary antibodies were used: rabbit/sheep antityrosine hydroxylase (TH) (1:300, Pel-Freez, Rogers, AK), mouse/goat anti-FoxA2/HNF3β (1:100, Santa Cruz Biotechnology, Santa Cruz, CA); mouse/rabbit anti-β-III-tubulin (TuJ1) (1:500, Covance, Berkeley, CA), mouse anti-Islet1 (1:100 and 1:500, Developmental Studies Hybridoma Bank, Iowa City, IA). The appropriate fluorescent-labeled secondary antibodies (1:500, Alexa Fluor goat or donkey anti-rabbit, -mouse, -rat or -goat 488, 568, 594, 647; Invitrogen Corporation) were applied for visualization, and nuclei were counterstained with Hoechst 33342 (5 μg/ml; Invitrogen Corporation). The specificity of the primary antibodies used in this study has been validated by our laboratory in cells and tissues of several species including human or have been published (Nelander et al., 2009) .
Cell counts
Quantitative analysis of immunocytochemistry was performed on randomly selected confocal fields from at least two independent differentiation experiments. In each field, images of separate channels (Hoechst, 488, 568, 594) were acquired at 40× magnification on an integrated confocal microscope (LSM510/Meta, Carl Zeiss) and stereology workstation (StereoInvestigator, MBF Bioscience, Inc., Williston, VT), where images of cells in independent channels and merged images were counted. For β-tubulin expression, we identified high expression when signal was detectable using the following parameters on the confocal microscope: pinhole 322 μm, Detector gain 393, Amplifier Offset 0 V. We considered low expression when signal was detectable using the following parameters on the confocal microscope: pinhole 163 μm, Detector gain 588, Amplifier Offset 0 V. On average, 20-25 visual fields were acquired per 16-mm coverslip, and a total of 4000-8000 Hoechst cells were counted per experiment in a blinded manner by at least two investigators.
Statistical analysis
Data were analyzed by Tukey's ANOVA using software (JMP, SAS Institute Inc, Cary, NC). Statistical significance was achieved at p b 0.05.
